Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.68), $0.01 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $17.67 million.

GUIDANCE:

Tandem Diabetes sees FY2016 revenue of $108-115 million, versus the consensus of $108.5 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.